Cumberland downgraded to Market Perform from Outperform at Wells Fargo Wells Fargo downgraded Cumberland Pharmaceuticals citing risk to the Acetadote franchise after the FDA approved Innopharma's potential generic. The firm lowered its price target range for shares to $6-$7 from $8-$9.
Cumberland announces approval of Caldolor injection Cumberland announced the approval of Caldolor Injection for pediatric patients six months of age and older. The approval was based on data submitted to the U.S. Food and Drug Administration (FDA) as part of a post-marketing commitment following approval of Caldolor in adults in 2009. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug approved for use in pediatric patients.